Pulmonx Announces Upcoming Financial Results Conference Call
In an important update for investors and stakeholders, Pulmonx Corporation, a recognized leader in minimally invasive treatment options for lung diseases, has confirmed they will share their financial results for the second quarter of 2025. This announcement was made recently in Redwood City, California, as anticipation grows around the company's performance during this timeframe.
Date and Time of Results Release
Pulmonx Corporation will release its second quarter financial results after the close of trading on a scheduled date. Following the release, the company has arranged a conference call where management will discuss these results in depth. Investors and analysts are invited to join this call, set to begin shortly after the results are published in the early afternoon.
Access to Live Webcast
For those unable to attend the live call, Pulmonx will provide an archived webcast accessible on their Investor Relations website. This format allows for continuous access to the company's updates, ensuring that all interested parties can stay informed on vital information and future plans.
About Pulmonx Corporation
Pulmonx Corporation has quickly established itself as a frontrunner in the field of minimally invasive techniques for chronic obstructive pulmonary disease (COPD). Through innovative products such as the Zephyr® Endobronchial Valve and the Chartis® Pulmonary Assessment System, the company aims to enhance the quality of life for patients suffering from severe emphysema and COPD. These tools have been recognized as standard options in treatment protocols worldwide, and Pulmonx is proud to have received FDA breakthrough designation for its Zephyr Valve, paving the path for its commercialization across various countries.
Looking to the Future
As Pulmonx Corporation continues to thrive, their innovative respiratory solutions are set to make significant contributions to the healthcare landscape, particularly in treating lung ailments. The continuing release of clinical data and management updates will be pivotal for investors interested in the company's trajectory within the medical field focused on lung health.
Contact Information for Investors
For further inquiries, interested parties may reach out to Jeremy Feffer, who represents LifeSci Advisors. He is available via email for any investor-related questions, providing direct access to information regarding Pulmonx Corporation's operations and financial outlook.
Frequently Asked Questions
1. When will Pulmonx announce its Q2 2025 financial results?
Pulmonx will announce its financial results after the close of trading on a specified date.
2. How can I access the financial results conference call?
You can listen to the live conference call and archive through the Investors section of Pulmonx's website.
3. What is the focus of Pulmonx Corporation?
Pulmonx focuses on minimally invasive treatments for chronic obstructive pulmonary disease and other lung diseases.
4. Where are Pulmonx's products available?
Products like the Zephyr Valve are commercially available in over 25 countries and included in treatment guidelines.
5. Who should I contact for investor-related questions?
Jeremy Feffer from LifeSci Advisors is the contact person for any investor inquiries regarding Pulmonx Corporation.
